PARIS (Agefi-Dow Jones)–Pharmaceutical groups Ipsen and Marengo Therapeutics announced on Monday that they have entered into a strategic partnership to develop two clinical-stage precision immuno-oncology treatment candidates.
“This collaboration will benefit not only from Marengo’s unique expertise in R&D concerning a new mechanism of activation of T cells, but also from Ipsen’s international presence in oncology within the framework of clinical development and commercialization”, have the two companies said in a statement.
As part of this partnership, Ipsen will make an initial payment of $45 million (approximately €44 million) to the British company Marengo Therapeutics, as well as subsequent payments which could reach up to $1.59 billion if all steps are respected, in addition to the payment of progressive royalties on sales.
-Dimitri Delmond, Agefi-Dow Jones; +33 (0)1 41 27 47 31; [email protected] ed: VLV
Agefi-Dow Jones The financial newswire
Dow Jones Newswires
August 01, 2022 01:26 ET (05:26 GMT)